Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointesitnal Malignancies

Trial Profile

Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointesitnal Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Sorafenib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Feb 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Jan 2017 as per ClinicalTrials.gov record.
    • 18 Nov 2015 Status changed from active, no longer recruiting to completed, as published in the Investigational New Drugs.
    • 18 Nov 2015 Results published in the Investigational New Drugs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top